Immatics N.V.(IMTX) - 2023 Q4 - Annual Report

extended TCR Bispecifics platform. In parallel, the clinical data for our PRAME cell therapy, IMA203 GEN1, in conjunction with highly constructive FDA discussions, reinforces our confidence in advancing this asset toward a registration-enabling Phase 2/3 clinical trial in melanoma, while laying the groundwork to transition into a fully equipped commercial-stage company." Exhibit 99.1 Immatics Announces Full Year 2023 Financial Results and Corporate Update Houston, Texas and Tuebingen, Germany, March 21, 202 ...